Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Three putative
prostate cancer
-susceptibility genes, RNASEL/HPC1 at 1q24, MSR1 at 8p22, and
ELAC2
/HPC2 at 17p11, have recently been identified. Our objective was to investigate somatic mutations in these genes in sporadic
prostate cancer
. We analyzed 39 clinical
prostate cancer
specimens, 10
prostate cancer
xenografts (LuCaP series), and 4
prostate cancer
cell lines (LNCaP, DU145, PC-3, and MPC-3) for genetic changes using denaturing high-performance liquid chromatography and direct sequencing in order to screen the whole coding regions of RNASEL and MSR1, as well as exons 7 and 17 of
ELAC2
. The known 471delAAAG truncating mutation was found in the RNASEL gene in cell line LNCaP. The only new missense variation in RNASEL, Gly296Val, was found in cell line DU145, but not in any other samples. RNASEL and
ELAC2
also showed the common missense polymorphic changes. A previously reported truncating mutation (Arg293X) was found in MSR1 in the germ line of one individual. Our results indicate that inactivation of the RNASEL,
ELAC2
, or MSR1 genes by somatic mutation is a rare phenomenon in sporadic
prostate cancer
.
...
PMID:Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer. 1469 91
The potential
prostate cancer
susceptibility gene
ELAC2
has a Caenorhabditis elegans homolog (which we call hoe-1, for homolog of
ELAC2
). We have explored the biological role of this gene using RNAi to reduce gene activity. We found that worms subjected to hoe-1 RNAi are slow-growing and sterile. The sterility results from a drastic reduction in germline proliferation and cell-cycle arrest of germline nuclei. We found that hoe-1 is required for hyperproliferation phenotypes seen with mutations in three different genes, suggesting hoe-1 may be generally required for germline proliferation. We also found that reduction of hoe-1 by RNAi suppresses the multivulva (Muv) phenotype resulting from activating mutations in ras and that this suppression is likely to be indirect. This is the first demonstration of a biological role for this class of proteins in a complex eukaryote and adds important information when considering the role of
ELAC2
in
prostate cancer
.
...
PMID:The Caenorhabditis elegans homolog of the putative prostate cancer susceptibility gene ELAC2, hoe-1, plays a role in germline proliferation. 1472 85
Prostate cancer
is the most frequent cancer among men in most developed countries, yet little is known about its causes. Older age, African ancestry and a positive family history of
prostate cancer
have long been recognized as important risk factors. The evidence that genetics probably plays a critical role is based on a variety of study designs, including case-control, cohort, twin and family-based, all of which are reviewed in detail. The search for
prostate cancer
susceptibility genes by linkage studies offered early hope that finding genes would be as 'easy' as finding genes for breast cancer and colon cancer susceptibilities. However, this hope has been dampened by the difficulty of replicating promising regions of linkage. This review provides updates on recent developments, and a broad view of the disparate findings from different linkage studies. Early linkage results have provided targeted candidate regions for
prostate cancer
susceptibility loci, including HPC1 on chromosome 1q23-25, PCAP on chromosome 1q42-43, CAPB on chromosome 1p36, linkage to chromosome 8p22-23, HPC2 on chromosome 17p, HPC20 on chromosome 20q13, and HPCX on chromosome Xq27-28. These linkage findings lead to refined mapping and mutation screening of several strong candidate genes, including
ELAC2
, RNASEL and MSR1. Up to now, a total of 10 genome-wide linkage scans for
prostate cancer
susceptibility have been completed, and are reviewed. Furthermore, recent findings that Gleason's grade, a measure of aggressiveness of
prostate cancer
, is linked to several genomic regions are reviewed. Finally, the roles of environmental and dietary risk factors, and common genetic polymorphisms of genes likely to play a role in common forms of
prostate cancer
, are briefly discussed within in the context of searching for genes that influence
prostate cancer
risk.
...
PMID:The complex genetic epidemiology of prostate cancer. 1474 51
Multiple factors contribute to the high incidence and prevalence of
prostate cancer
including race, ethnicity, diet, environment, widespread awareness through prostate-specific antigen screening and genetics. Linkage analysis has identified several candidate sites for
hereditary prostate cancer
gene loci. Molecular studies have also identified genes that are frequently altered in sporadic
prostate cancer
. It appears that due to the heterogeneity of
prostate cancer
, multiple genes may be involved in the neoplastic process.
...
PMID:Molecular genetics of human prostate cancer. 1475 25
Results from over a dozen
prostate cancer
susceptibility genome-wide scans, encompassing some 1,500
hereditary prostate cancer
families, indicate that
prostate cancer
is an extremely heterogeneous disease with multiple loci contributing to overall susceptibility. In an attempt to reduce locus heterogeneity, we performed a genomewide linkage scan for
prostate cancer
susceptibility genes with 36 Jewish families, which represent a stratification of
hereditary prostate cancer
families with potentially increased locus homogeneity. The 36 Jewish families represent a combined dataset of 17 Jewish families from the Fred Hutchinson Cancer Research Center-based
Prostate Cancer
Genetic Research Study dataset and 19 Ashkenazi Jewish families collected at Johns Hopkins University. All available family members, including 94 affected men, were genotyped at markers distributed across the genome with an average interval of <10 centimorgans. Nonparametric multipoint linkage analyses were the primary approach, although parametric analyses were performed as well. Our strongest signal was a significant linkage peak at 7q11-21, with a nonparametric linkage (NPL) score of 3.01 (P = 0.0013). Simulations indicated that this corresponds to a genomewide empirical P = 0.006. All other regions had NPL P values >/=0.02. After genotyping additional markers within the 7q11-21 peak, the NPL score increased to 3.35 (P = 0.0004) at D7S634 with an allele-sharing logarithm of odds of 3.12 (P = 0.00007). These studies highlight the utility of analyzing defined sets of families with a common origin for reducing locus heterogeneity problems associated with studying complex traits.
...
PMID:Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. 1476 43
The E-cadherin (CDH1) gene has been associated with prostate carcinogenesis. The C/A polymorphism--160 base pairs relative to the transcription start site has been shown to decrease gene transcription. We analyzed the association between this polymorphism and the risk of sporadic, familial (2 close relatives) and hereditary (3 or more close relatives)
prostate cancer
. We combined data from 3 population-based epidemiologic studies in Sweden encompassing altogether 1,036
prostate cancer
cases and 669 controls that were genotyped for the short nucleotide polymorphism. Odds ratios with 95% confidence intervals were estimated through unconditional logistic regression. We found no significant association between the A-allele and sporadic (OR = 1.0; 95% CI = 0.8-1.2) or familial (OR = 1.4; 95% CI = 0.9-2.2)
prostate cancer
. In contrast, risk of hereditary cancer was increased among heterozygote CA carriers (OR = 1.7; 95% CI = 1.0-2.7) and particularly among homozygote AA carriers (OR = 2.6; 95% CI = 1.4-4.9). Our data indicate that the -160 single nucleotide polymorphism in CDH1 is a low-penetrant
prostate cancer
susceptibility gene that might explain a proportion of familial and notably
hereditary prostate cancer
.
...
PMID:-160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. 1496 71
The loss of cell cycle control is believed to be an important mechanism in the promotion of carcinogenesis. CDKN1B (p27) belongs to the Cip/Kip family and functions as an important cell cycle gatekeeper. Several lines of evidence from clinical studies and laboratory experiments demonstrate that CDKN1B is an important tumor suppressor gene in
prostate cancer
etiology. In addition, a case-control study has shown that the 326T/G (V109G) polymorphism in CDKN1B is associated with advanced
prostate cancer
. In light of the evidence for linkage between the chromosomal location of the CDKN1B gene (12p13) and
prostate cancer
susceptibility in several
hereditary prostate cancer
(
HPC
) populations, we hypothesized that sequence variants of CDKN1B play a role in
HPC
. To test this hypothesis, we first resequenced this gene in 96
HPC
probands to identify germ-line mutations and sequence variants. We then genotyped the identified sequence variants among all family members of 188
HPC
families and tested for their cosegregation with
prostate cancer
. In total, 10 sequence variants were identified, including three nonsynonymous changes. A family-based test, which is free from the effects of population stratification, revealed a significant association between single nucleotide polymorphism (SNP) -79C/T and
prostate cancer
(with a nominal P of 0.0005). The C allele of -79C/T was overtransmitted from parents to their affected offspring. Evidence for this association was primarily contributed by affected offspring whose age at diagnosis was <65 years. Together with the previous association study in a sporadic
prostate cancer
population, our new findings additionally suggest that germ-line variants of this gene play a role in
prostate cancer
susceptibility.
...
PMID:A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. 1502 35
Several genetic loci are suspected to be involved in
hereditary prostate cancer
, including the
hereditary prostate cancer
1 (HPC1) locus at chromosome 1q24-25. The ribonuclease L (RNase L) gene has been reported as the putative
hereditary prostate cancer
gene located at HPC1. If this is the case, mutations of RNase L should be found at a greater frequency in familial cancers than in sporadic prostate cancers. Examination of familial and sporadic cases of
prostate cancer
by polymerase chain reaction and DNA sequencing resulted in a mutational frequency rate that was not statistically different between the 2 forms of the disease. These results suggest that the mutations examined within this study are rare and may contribute to very few familial prostate cancers.
Clin
Prostate Cancer
2003 Dec
PMID:Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer. 1504 Aug 62
The tumor suppressor functions of PTEN and CDKN1B have been extensively characterized. Recent data from mouse models suggest that, for some organs, the combined action of both PTEN and CDKN1B has a stronger tumor suppressor function than each alone; for the prostate, heterozygous knockout of both genes leads to 100% penetrance for
prostate cancer
. To assess whether such an interaction contributes to an increased risk of
prostate cancer
in humans, we performed a series of epistatic PTEN and CDKN1B interaction analyses in a collection of 188 high-risk
hereditary prostate cancer
families. Two different analytical approaches were performed; a nonparametric linkage (NPL) regression analysis that simultaneously models allele sharing at these two regions in all families, and an ordered subset analysis (OSA) that assesses linkage evidence at a target region in a subset of families based on the magnitude of allele sharing at the reference region. The strongest evidence of interaction effect was observed at 10q23-24 and 12p11-13 from both the NPL regression analysis (P = 0.0002) in all families and the OSA analyses in subsets of families. A LOD-delta of 3.15 (P = 0.01) was observed at 10q23-24 among 54 families with the highest NPL scores at 12p11-13, and a LOD-delta of 2.63 (P = 0.02) was observed at 12p11-13 among 34 families with the highest NPL scores at 10q23-24. The evidence for the interaction was stronger when using additional fine-mapping markers in the PTEN (10q23) and CDKN1B (12p13) regions. Our data are consistent with epistatic interactions between the PTEN and CDKN1B genes affecting risk for
prostate cancer
and demonstrate the utility of modeling epistatic effects in linkage analysis to detect susceptibility genes of complex diseases.
...
PMID:Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage. 1518 41
Prostate cancer
is the most frequent malignant tumor among men over 50 years old. Its incidence varies according to countries and ethnic group. Known risk factors are race and positive family history of the disease. Familial aggregation (at least 2 cases in the family) is observed in about 20% of cases and an hereditary form of
prostate cancer
in 5%. This proportion increases with younger age at diagnosis. Six putative loci are already identified but undoubtedly, others will be found in forthcoming studies. The genetic heterogeneity observed in
hereditary prostate cancer
reflects variety of origins of the studied families. In some families, aggregation of
prostate cancer
and other cancers suggests the involvement of common predisposing genes. In other familial and in sporadic cases, the genetic component should be polygenic:
prostate cancer
wouldn't result to segregation of a major gene mutations transmitted according to a monogenic inheritance, but rather to sharing of alleles at many loci, each contributing to a small increase in cancer risk. Indeed, several genetic polymorphism were associated with an increased risk of developing
prostate cancer
and could explain the variations of
prostate cancer
incidence observed between populations.
...
PMID:[Genetic susceptibility to prostate cancer]. 1519 Apr 76
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>